MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
The frequent overexpression of CD46 in malignant tumors has provided a basis to use vaccine-lineage measles virus (MeV) as an oncolytic virotherapy platform. However, widespread measles seropositivity limits the systemic deployment of oncolytic MeV for the treatment of metastatic neoplasia. Here, we...
Główni autorzy: | Miguel Ángel Muñoz-Alía, Rebecca A Nace, Alexander Tischer, Lianwen Zhang, Eugene S Bah, Matthew Auton, Stephen J Russell |
---|---|
Format: | Artykuł |
Język: | English |
Wydane: |
Public Library of Science (PLoS)
2021-02-01
|
Seria: | PLoS Pathogens |
Dostęp online: | https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1009283&type=printable |
Podobne zapisy
-
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
od: Miguel Á. Muñoz-Alía, i wsp.
Wydane: (2024-02-01) -
Neutralizing Antibody Response to Genotypically Diverse Measles Viruses in Clinically Suspected Measles Cases
od: Sunil R. Vaidya, i wsp.
Wydane: (2023-11-01) -
Effect of measles prevalence and vaccination coverage on other disease burden: evidence of measles immune amnesia in 46 African countries
od: Ryoko Sato, i wsp.
Wydane: (2021-12-01) -
A Combined Ultrafiltration/Diafiltration Process for the Purification of Oncolytic Measles Virus
od: Daniel Loewe, i wsp.
Wydane: (2022-01-01) -
Oncolytic Measles Virus Encoding MicroRNA for Targeted RNA Interference
od: Sophie C. Anker, i wsp.
Wydane: (2023-01-01)